AstraZeneca Senior Executive Team • Sarah Hemingway, International Marketing Coordinator: • Simon Lowth, Executive Director & Chief Financial sarah.hemingway@astrazeneca.com Officer:[email protected] • Jonathan Hunt, VP & Head, IR: [email protected] • David Smith, Executive Vice President, Global Operations & • Prashaant Huria, Head, Regional Information Systems, CEEMEA: Information Services: [email protected] [email protected] • Katarina Ageborg, Chief Compliance • Leif Johansson, Non-Executive Chairman, Nomination and Officer:[email protected] Governance Committee: [email protected] • Lynn Tetrault Executive Vice President, Human Resources & Corporate • Adrian Kemp, Company Secretary: [email protected] Affairs: [email protected] • Sarah Lindgreen, Associate, Global Media Relations: • Jeff Pott, General Counsel: [email protected] [email protected] • Jan Lundberg, Executive Vice President, Discovery Research: 7 Senior Exec, emails are configured in AstraZeneca format. There is [email protected] no confirmed evidence that any are real addresses. May bounce. • Ellen Madford, Manager, Sourcing: [email protected] • Pascal Soriot, Executive Director & Chief Executive Officer: • Mats Marfalt, Project Manager: [email protected] [email protected] • Rudy Markham, Non-Executive Director & Chairman, Audit • Mene Pangalos, Executive Vice President, Innovative Committee: [email protected] Medicines: [email protected] • Sonia Matadial, Associate Clinical Project Manager: • Bahija Jallal, Executive Vice President, MedImmune: [email protected] [email protected] • Neil McCrae, VP, Corp Comm Grp: [email protected] • Briggs Morrison, Executive Vice President, Global Medicines • David Morgan, Head, Information Systems: Development: [email protected] [email protected] • Paul Hudson, Executive Vice President, North America: • Brian Morris, Manager, IS Quality: [email protected] [email protected] • Ken Morris, Vice President, IT Sourcing Strategy: • Ruud Dobber, Executive Vice President, Europe: [email protected] [email protected] • Bo Norden, Team Leader: [email protected] • Mark Mallon, Executive Vice President, International: • Robert W. Perkins, VP, Pub Policy & Promotional Affairs: [email protected] [email protected] • Plamen Petrov, Principal Scientist: [email protected] AstraZeneca PLC • Iain Rankin, Head, Information Management Delivery Centre, 2 Kingdom Street Stockport, UK: [email protected] Paddington, London W2 6BD • Carl Richards, Director, Information Systems, Global: United Kingdom [email protected] corporate phone: +44-20-7304-5000 • Dame Nancy Rothwell, Non-Executive Director & Chairman, Science 44 20 7604 8000; fax: 44 20 7604 8151 Committee: [email protected] Investor Relations: [email protected] • Hitesh Sanganee, Team Leader: [email protected] • Amy Allen, Manager, Clinical Research: [email protected] • Leslie Schaefer, Brand Leader: [email protected] • Colin Bergstrand, Director, Programs: • Adin Spring, Project Manager: [email protected] [email protected], +44-7920-587-712 • Eileen Stowe, Manager, Occupational Health: • Michael Boas Manager, Global Brand: [email protected] [email protected] • Fred Taylor, Project Manager: [email protected] • Neil Broster, Manager, IS Quality & Test: • John Tyson, Project Manager, Information Technology: [email protected] [email protected] • Daniel Brown, Manager, Formulation Development: • Annmarie Ungaro, Project Manager: [email protected] [email protected] • Bruce Burlington, Non-Executive Director & Member, Science • Baroness Vadera, Non-Executive Director & Member, Audit Committee: [email protected] Committee: [email protected] • Jared Cohen, Manager, Marketing Manager: • John Varley, Senior Non-Executive Director & Chairman, [email protected] Remuneration: [email protected] • Charles Cottman, Project Coordinator: • Marcus Wallenberg, Non-Executive Director & Member, Science [email protected] Committee: [email protected] • Jean-Philippe Courtois, Non-Executive Director & Member, Audit • James Ward-Lilley, Regional Vice President, UK: Committee: [email protected] +44-207-604-8122 • Charlotte Cousins, Administrative Coordinator, Purchasing: • Barbara Wenrich, Project Coordinator: [email protected] [email protected] • Assunta Cuccia, Study Delivery Team Leader: • Nicklas Westerholm, Head, Global API Supply, UK: [email protected] [email protected], +44-207-604-8123 • Polina Denisenko, Mgr, PR, Russia: [email protected] AstraZeneca US • Vikram Dev, Project Manager: [email protected] AstraZeneca PLC / 1800 Concord Pike • Jim Dolceamore, Manager, Lab Engineering: P.O. Box 15437 [email protected] Wilmington, DE 19850-5437 USA • Mike Eastgate, Manager, IT Services: corporate phone: +1-302-886-3000 [email protected] • Michael Ade, Project Manager, Enterprise IS: • Karen Edwards, Director, Global Portfolio, Digital: [email protected] [email protected], +44-7780-956-187 • Gary Csaniz, Senior Manager, Enterprise Data Architecture: • Karl Hard, Director, Investor Relations, UK Director: [email protected] [email protected], +44-207-604-8124 • Julien Durand, Regional Compliance Officer & Ethical Innovation Lead, • Kim Harrington, HCP Brand Leader: [email protected] Latin America: [email protected] • Philip Hayes, Category Leader, Contract Management: • Rich Fante, President, US Business & Regional Vice President, [email protected] Americas: [email protected] • Caroline Hempstead, VP, Corp Affairs, Global: • Johan Hoegstedt, Vice President, Managed Markets: [email protected] [email protected]
• Rod Hoffman, Senior Manager, Business Information: • Darren McKerrecher, Associate Director, Medicinal Chemistry: [email protected] [email protected] • Deborah Kauffman, Vice President, Human Resources: • Stephen Partridge, Global Director, Clinical Project Management: [email protected] [email protected] • Jonathan Kirby, Chief Information Officer: +44-20-7604-8185 or • Gopal Sharma, Senior Manager, Strategy: +44-20-7684-8186 [email protected] • Marion McCourt, Chief Operating Officer: • Mike Snowden, Vice President, Discovery Sciences: [email protected] [email protected], +44-1625-517-077 • Kathy Monday, Regional Vice President, Supply, Americas: • Kevin Teburi, Associate Project Director & Service Delivery Leader: [email protected] [email protected] • David Nicoli, Vice President, Corporate Affairs: • Maria-Elena Theoclitou, Group Manager, Clinical Development & [email protected] Leader, Study Operations Programme: • Linda Palczuk, Vice President, Sales & Marketing, Cornerstone: [email protected] [email protected] • Mark Weaver, Global Head, Archives & Records Management, • Lisa Schoenberg, Vice President, Sales & Marketing, Growth: AstraZeneca R&D, Charnwood: [email protected] [email protected] • Peter Webborn, Director, Global Pharmacokinetics: • Matt Talbot, Senior Manager, Information Services Business Analysis: [email protected] [email protected] • John Yee, Vice President & Head Medical Officer: AstraZeneca Czech Republic, s.r.o. [email protected] • Katerina Honajzerova, Sales & Marketing Coordinator, Cardiovascular • Angela Yochem, Chief Technology Officer: & Diabetology: +420-2-2280-7111 [email protected] • Josef Vaclavik, Manager, Information Technology: [email protected], +420-2-2280-7126 AstraZeneca AB • Robert Weigl, President, AstraZeneca Czech Republic: AstraZeneca Nordic Headquarters [email protected], +420-2-2280-7210 Karlebyhus, Astra Allen SE-151 85 Soedertaelje ph: +46-8-5532-6000 fax: +46 (0) 8 553 290 00 email: [email protected] • Peter Alvarsson, Head, Operational Excellence: +46-8-5525-4480 • Magnus Blomberg, Director, Global Project & Change: [email protected], +46-8-5525-7952 • Erik Briselius, Senior Solutions Architect Manager: [email protected], +46-4-633-7616 • Clas Furusten, Project Manager, Information Systems: [email protected], +46-8-5532-9029 • Benny Hansen, Manager, Service Process Support: [email protected], +46-8-5532-4215 • Osborn Harmestad, Manager, Strategy & Portfolio Manager Direct: [email protected], +46-8-5525-5977 • Lars Klinga, Manager, Infrastructure Commercial Control: [email protected], +46-8-5532-8772 • Tord Larfe, Project Manager, Information Systems: [email protected], +46-8-5532-7308 • Michael Oehman, Manager, IT Infrastructure: [email protected], +46-8-5532-6360 • Tomas Wahlgreen, Manager, Business Relationship, Maintenance & Document Management: [email protected], +46-953-200-9196
AstraZeneca R&D, Charnwood +44-1509-644-000 • Roland Bogush, Director, Clinical IT Business Engagement: [email protected], +44-1509-645-009 or +44-7867-905-971 • Peter Colman, Group Manager, Statistics & Programming: [email protected] • Janet Edwards, Chief of Staff, Clinical Development: [email protected] • Lesley France, Director, Statistics & Programming Section: [email protected] • Anne Galer, Senior Project Director, Innovative Medicines Oncology: [email protected] • Margaret Gold, Manager, Global IS Quality & Compliance: [email protected] • Mark Howard Manager, Global IS Risk & Security: [email protected], +44-1509-644-485 • Andrew Hudson, Global Head, Patient Safety Systems & Information Strategy: [email protected] • Amrik Mahal, Associate Director, Clinical: [email protected]
Dear Sir/Madam,
I write as a consumer concerned about AstraZeneca’s use of a controversial research lab headquartered in the UK, as well as the fate of hundreds of beagles once housed in the company’s (now closed) breeding compound in Sweden. My comments are sent in hope that individuals within AstraZeneca can raise awareness of these issues and seek ethical resolution.
I am disappointed that AZ initiated shipment of more than 300 beagles to experimentation labs, despite global outcry for several months. Various reports indicate AstraZeneca’s involvement in the air cargo transfer of these dogs to the lab at Astra AB. Though AZ let staff rehome some beagles, most are likely destined for AZ’s contracted toxicology lab, Huntingdon_Life_Sciences (H.L.S.).
“Bred for research” is a misnomer. The main difference between lab beagles and family dogs is luck. No companion animal is bred to endure a tube forced down the throat for nasal-gastric dosing. Toxins quickly overcome small animals. As seen in footage from seven H.L.S. investigations that span more than a decade
I respectfully ask you to advocate for the release of these beagles. If you are an AZ policymaker, I urge you to ensure transfer of the beagles to credible rescue groups. Some groups specialize in care/adoption for lab-released animals. There is no viable reason to label the beagles unadoptable.
These dogs spotlight a long-standing concern about AstraZeneca’s ties to Huntingdon_Life_Sciences, a contract research lab exposed for extraordinary animal abuse. A report published in 2009 disclosed images of wild-caught monkeys squashed in cages for 30-hour transport to H.L.S. in Cambridgeshire. Inside the primate toxicology unit, an observer saw monkeys strapped to restraint chairs while dosed via tube or inhalation. Animals suffered rectal prolapse, a recognized stress gauge in primates. One monkey gnawed off an entire finger. They vomited and salivated throughout tests. During an inhalation study, three moneys died in agony from collapsed or obstructed lungs.
The investigator recorded filthy cages and animals who self-mutilated to cope with stress. A monkey shredded her face and had to eat with a feeding tube. Nearly 217 monkeys died for just five studies. These conditions define “normal” at H.L.S., a lab with U.S. Animal Welfare Act violations, the arrest of personnel on cruelty charges, more than 520 infringements of Good Laboratory Practice in England, and payoffs to the U.S. Agriculture Dept. for fraudulent records and animal welfare citations.
In an earlier investigation, two past H.L.S techs testified that animals were insufficiently anesthetized before painful procedures, such as extraction of bone marrow. Workers routinely mistreated dogs. For blood draws, they’d go "in and out about five times with the same needle, not hitting the vein. I saw coworkers grab dogs by the scruff, shout and swear, swing them by the scruff and slap them."
Biotechnology has undergone rapid expansion in recent years, with more human-based methods relevant to our health and safety. Conversely, animal experiments continue to mislead. One 2012 study found 47 of 53 “landmark” findings could not even be reproduced. “Too many ‘discoveries’...done in animals are wrong,” the report noted (C. Glenn Begley, former head of global cancer research at Amgen. Journal: Nature, Mar 2012). I urge AstraZeneca to lead advances in animal-free research and welcome your feedback on efforts to support its funding and development.
Please do the right thing: Release the Astra beagles for adoption and terminate business with Huntingdon_Life_Sciences.
Thank you for your valuable time and consideration,